Omeros Long Term Debt 2012-2025 | OMER
Omeros long term debt from 2012 to 2025. Long term debt can be defined as the sum of all long term debt fields.
|
Omeros Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $167 |
| 2023 | $213 |
| 2022 | $221 |
| 2021 | $313 |
| 2020 | $236 |
| 2019 | $158 |
| 2018 | $149 |
| 2017 | $83 |
| 2016 | $80 |
| 2015 | $50 |
| 2014 | $26 |
| 2013 | $15 |
| 2012 | $20 |
| 2011 | $14 |
|
Omeros Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-09-30 | $160 |
| 2025-06-30 | $151 |
| 2025-03-31 | $159 |
| 2024-12-31 | $167 |
| 2024-09-30 | $189 |
| 2024-06-30 | $191 |
| 2024-03-31 | $213 |
| 2023-12-31 | $213 |
| 2023-09-30 | $222 |
| 2023-06-30 | $222 |
| 2023-03-31 | $221 |
| 2022-12-31 | $221 |
| 2022-09-30 | $315 |
| 2022-06-30 | $314 |
| 2022-03-31 | $314 |
| 2021-12-31 | $313 |
| 2021-09-30 | $313 |
| 2021-06-30 | $313 |
| 2021-03-31 | $312 |
| 2020-12-31 | $236 |
| 2020-09-30 | $233 |
| 2020-06-30 | $163 |
| 2020-03-31 | $161 |
| 2019-12-31 | $158 |
| 2019-09-30 | $156 |
| 2019-06-30 | $153 |
| 2019-03-31 | $151 |
| 2018-12-31 | $149 |
| 2018-09-30 | $132 |
| 2018-06-30 | $130 |
| 2018-03-31 | $85 |
| 2017-12-31 | $83 |
| 2017-09-30 | $83 |
| 2017-06-30 | $82 |
| 2017-03-31 | $81 |
| 2016-12-31 | $80 |
| 2016-09-30 | $70 |
| 2016-06-30 | $70 |
| 2016-03-31 | $50 |
| 2015-12-31 | $50 |
| 2015-09-30 | $19 |
| 2015-06-30 | $21 |
| 2015-03-31 | $24 |
| 2014-12-31 | $26 |
| 2014-09-30 | $29 |
| 2014-06-30 | $31 |
| 2014-03-31 | $32 |
| 2013-12-31 | $15 |
| 2013-09-30 | $16 |
| 2013-06-30 | $18 |
| 2013-03-31 | $19 |
| 2012-12-31 | $20 |
| 2012-09-30 | $9 |
| 2012-06-30 | $10 |
| 2012-03-31 | $12 |
| 2011-12-31 | $14 |
| 2011-09-30 | $15 |
| 2011-06-30 | $17 |
| 2011-03-31 | $18 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.829B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $195.936B | 21.88 |
| EssilorLuxottica (ESLOY) | France | $142.091B | 0.00 |
| Stryker (SYK) | United States | $140.083B | 26.86 |
| Medtronic (MDT) | Ireland | $127.548B | 17.67 |
| Boston Scientific (BSX) | United States | $110.783B | 24.50 |
| Medline (MDLN) | United States | $58.526B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.093B | 0.00 |
| ResMed (RMD) | United States | $36.791B | 24.57 |
| GE HealthCare Technologies (GEHC) | United States | $36.615B | 17.54 |
| Agilent Technologies (A) | United States | $35.584B | 22.55 |
| Koninklijke Philips (PHG) | Netherlands | $30.091B | 17.86 |
| Terumo (TRUMY) | Japan | $21.610B | 25.26 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.115B | 11.76 |
| Insulet (PODD) | United States | $17.076B | 53.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.372B | 0.00 |
| Baxter (BAX) | United States | $10.173B | 8.72 |
| Sunny Optical Technology (SNPTF) | China | $8.485B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.921B | 25.86 |
| Demant (WILYY) | Denmark | $6.042B | 0.00 |
| Envista Holdings (NVST) | United States | $4.763B | 24.14 |
| Lantheus Holdings (LNTH) | United States | $4.601B | 14.02 |
| BillionToOne (BLLN) | United States | $4.056B | 0.00 |
| ICU Medical (ICUI) | United States | $3.577B | 22.71 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.263B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.160B | 14.91 |
| Haemonetics (HAE) | United States | $2.684B | 11.74 |
| Neogen (NEOG) | United States | $2.380B | 52.10 |
| Phibro Animal Health (PAHC) | United States | $2.118B | 18.66 |
| Perrigo (PRGO) | Ireland | $2.001B | 5.01 |
| LeMaitre Vascular (LMAT) | United States | $1.989B | 40.03 |
| Curaleaf Holdings (CURLF) | Canada | $1.642B | 0.00 |
| AtriCure (ATRC) | United States | $1.623B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.602B | 11.12 |
| Kestra Medical Technologies (KMTS) | United States | $1.571B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.446B | 63.36 |
| AdaptHealth (AHCO) | United States | $1.381B | 20.00 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.358B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.070B | 317.57 |
| Capricor Therapeutics (CAPR) | United States | $1.026B | 0.00 |
| InMode (INMD) | Israel | $0.906B | 9.93 |
| Tilray Brands (TLRY) | Canada | $0.875B | 0.00 |
| Valneva SE (VALN) | France | $0.868B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.757B | 0.00 |
| CeriBell (CBLL) | United States | $0.733B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.566B | 13.52 |
| Brainsway (BWAY) | Israel | $0.450B | 76.63 |
| Cerus (CERS) | United States | $0.430B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.398B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.396B | 0.00 |
| SNDL (SNDL) | Canada | $0.386B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.361B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.328B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.315B | 25.09 |
| Evolus (EOLS) | United States | $0.279B | 0.00 |
| Quanterix (QTRX) | United States | $0.268B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.243B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Sanuwave Health (SNWV) | United States | $0.213B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.205B | 18.42 |
| High Tide (HITI) | Canada | $0.203B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.201B | 59.17 |
| OraSure Technologies (OSUR) | United States | $0.197B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.182B | 0.00 |
| Organigram Global (OGI) | Canada | $0.174B | 0.00 |
| Accendra Health (ACH) | United States | $0.173B | 1.74 |
| Vireo Growth (VREOF) | United States | $0.170B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.168B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Apyx Medical (APYX) | United States | $0.142B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.134B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.129B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.42 |
| MacroGenics (MGNX) | United States | $0.108B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.100B | 0.00 |
| Biote (BTMD) | United States | $0.097B | 4.26 |
| Exagen (XGN) | United States | $0.074B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 25.38 |
| Sharps Technology (STSS) | United States | $0.051B | 0.00 |
| Nephros (NEPH) | United States | $0.044B | 31.54 |
| Cytosorbents (CTSO) | United States | $0.040B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.040B | 0.00 |
| Veru (VERU) | United States | $0.037B | 0.00 |
| Modular Medical (MODD) | United States | $0.035B | 0.00 |
| United-Guardian (UG) | United States | $0.030B | 15.35 |
| Jin Medical (ZJYL) | China | $0.022B | 0.00 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| INLIF (INLF) | China | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Agape ATP (ATPC) | $0.002B | 0.00 | |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |